

Appendix 1: Exclusion criteria

Subjects who satisfied any one of the following exclusion criteria were not eligible for this study:

- Transvesically measured postvoid residual volume >400 mL
- Currently in urinary retention
- Chronic urinary retention
- Medications impairing bladder contractibility
- Uncorrectable bleeding disorders or long-term anticoagulation that cannot be stopped
- Recent myocardial infarction or coronary artery stent placement
- Any of the following diseases which appear to involve the bladder: myasthenia gravis, diabetes neuropathy, multiple sclerosis, spinal cord injury, or Parkinson's disease
- Any patient with idiopathic atonic bladder
- Major pelvic fractures that involved damage to the external urinary sphincter
- Recently completed definitive radiation therapy for prostate cancer
- Active localized or systemic infections; including active urinary tract infection
- Active cystolithiasis, urethral strictures, bladder neck contracture, or acute prostatitis affecting bladder function
- If patient's PSA value >PSA age-adjusted normal value, patient needs to have a negative biopsy before participating in the study
- Confirmed malignancy of the prostate
- Bladder cancer treated with TURBT within 12 months or any patients treated with BCG
- Bilateral hydronephrosis on renal ultrasound
- Urethral strictures or a residual volume >400 mL
- Immunocompromised
- Previous TURP

PSA: prostate-specific antigen; TURBT: transurethral resection of bladder cancer; BCG: Bacillus Calmette-Guerin; TURP: transurethral resection of the prostate.